Manager, Commercialization Funding
Tel: (848) 932-4156
bajpaima@research.rutgers.edu
![biomedical research](/sites/default/files/styles/16x9_full_default_1x/public/2022-02/Biomedical%20Research%20%28005%29.jpg?h=d8102449&itok=FySbiVTW)
The HealthAdvance Fund®
Advancing Biomedical Innovations
Advancing Biomedical Innovations
As part of the Rutgers Optimizes Innovation initiative, HealthAdvance Fund® provides commercialization funding to assist the development of early-stage life sciences technologies and make them more attractive for continued follow-on investments from industry partners and external investors.
About the Rutgers HealthAdvance Fund®
HealthAdvance Fund® is the funding platform of Rutgers Optimizes Innovation (ROI) program established with a $4 million grant received under the National Institutes of Health (NIH) Research Evaluation And Commercialization Hub (REACH). The program aims to energize the innovation culture across all university campuses to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics, and tools to improve health and patient care and train the next generation of innovators.
![Illustration of stethoscope on top of heartbeat sinus wave](/sites/default/files/styles/4x3_full_default_1x/public/2021-01/steth.jpg?h=88c22e25&itok=gWbYdDzh)
Pre-Qualification Guidelines & Form
Find out more about eligibility and application requirements for pre-qualification and the application process and timeline.
![A close-up of a monthly calendar](/sites/default/files/styles/4x3_full_default_1x/public/2021-01/calendar-660670_1920.jpg?h=2f83cd36&itok=2FR3bfbx)
Meet the Mentors-in-Residence
Our Mentors-in-Residence (MIRs) are individually matched to the Innovator teams that have been invited to submit a full application to the program and collaborate with their matched Innovators to craft compelling proposals for a commercially viable product or solution, with a strong focus on improving human health.
![A light bulb hanging with the word Mentor lit up inside](/sites/default/files/styles/4x3_full_default_1x/public/2021-01/shutterstock_526978822%20%281%29.jpg?h=c0ef59e8&itok=mC3Pjb-P)
Contact the Team
Associate Director, Commercialization Funding
Tel: (848) 932-4487
pragati.sharma@rutgers.edu
Executive Director, New Ventures
Tel: (848) 932-4551
vincent.smeraglia@rutgers.edu
Assistant Program Manager, New Ventures & Commercialization Funding
alb422@research.rutgers.edu
Recently Funded Projects
![Knapp Image](/sites/default/files/styles/16x9_one_third_default_1x/public/2021-08/Knapp-img.png?h=e7f7be8c&itok=KkNdx4-V)
We have identified potent small molecule MIF inhibitors that reduce inflammation-associated cytokines in blood cell and mouse assays, and simultaneously exhibit favorable drug likeness properties including oral availability. They hold promise for the treatment of human inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease.
![Ganapathy-Pierce-picture1](/sites/default/files/styles/16x9_one_third_default_1x/public/2021-08/GANAPATHY-PIERCE%20picture1.png?h=56691f0e&itok=oyBInnrH)
This project aims to advance nanoparticle-based contrast agents for pre-clinical imaging of tumors in small animals. The project focuses on (i) scaling up contrast agent synthesis, (ii) assembly of a prototype imaging system, and (iii) proof of concept studies to monitor tumor growth and response to therapy.
![3D Illustration: 360-degree spherical panorama view inside biofilm of antibiotic resistant bacteria](/sites/default/files/styles/16x9_one_third_default_1x/public/2021-07/shutterstock_449656513.jpg?h=04a36868&itok=pE95L69W)
The prevention of microbial adhesion and biofilm formation on medical device/tissue interfaces is an urgent and unmet need. Thi surface functionalization technology, which is specifically effective in preventing biofilm formation on medical devices, such as implants, aims to address this critical healthcare problem.
![Cellular level image](/sites/default/files/styles/16x9_one_third_default_1x/public/2021-05/ss673941226.png?h=5d605bba&itok=g-IbC18c)
The research team is developing a Cryptococcus fungal vaccine (HK-fbp1) that has shown cross protection against multiple major invasive mycoses, including Cryptococcus species, Aspergillus fumigatus, and Candida albicans. Its protection remains effective against Cryptococcus and Aspergillus in certain immunocompromised hosts, such as CD4 T cell-depleted mice, a condition mimicking AIDS patients.
![Rutgers Shield Logo](/themes/custom/rutgers_ored/images/rutgers-placeholder-16_9.jpg)
Aberrant expression of bone morphogenetic proteins (BMP) has been shown to promote age-related diseases including cancer and Alzheimer’s disease. The research group has developed small molecular inhibitors targeting a BMP receptor that has never been targeted before, aiming to develop this novel class of compounds into a drug for the treatment of cancer and Alzheimer’s disease.
![Molecular structure](/sites/default/files/styles/16x9_one_third_default_1x/public/2020-11/HealthAdvance_Ebright%20%28002%29.jpg?h=4d37cc35&itok=SWks0kls)
The team is developing a novel, first-in-class, orally-available drugs efficacious against tuberculosis and non-tuberculous mycobacterial lung infections. The candidates, RifaAAPs, are active against drug-susceptible, drug-resistant, multi-drug-resistant, and extensively-drug-resistant strains, have lower resistance emergence than current drugs, have higher sterilizing activity than current drugs, and have additive activity in combination with current drugs.
![Illustration of how therapeutic works in patients](/sites/default/files/styles/16x9_one_third_default_1x/public/2021-03/HealthAdvance_DongfangLiu.png?h=2c46d874&itok=PPLnMFYG)
Globally, there are 800,000 new cases of hepatocellular carcinoma (HCC) per year. Treatments are marginally effective today. The team developed a CD147-CAR-NK-based immunotherapy for HCC by re-engineering NK cells to target the specific HCC cell marker CD147, and thereby kill the HCC effectively and safely.